anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Closed-loop strategy is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosages based on the sensor's readings. A dual-hormone closed-loop strategy would regulate glucose levels through the infusion of two hormones: insulin and glucagon.

The investigators aim to conduct the 1st randomized cross-over trial comparing single- hormone and dual-hormone closed-loop strategy to regulate overnight glucose levels. The investigators aim to compare the two interventions for 10 hours in two subgroups of adults with type 1 diabètes. Patients from both subgroups will present documented nocturnal hypoglycemia. One subgroup will consist of patients with hypoglycemia unawareness while the other subgroup will consist of patients with hypoglycemia unawareness. This study will allow to determine if there is a greater benefit of a closed-loop strategy in a higher-risk hypoglycemia unaware group.
The use of benzodiazepines, including alprazolam, exposes users to the risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death [see Drug Abuse and Dependence ( 9.2)]. 

Before prescribing alprazolam and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction (e.g., using a standardized screening tool). Use of alprazolam, particularly in patients at elevated risk, necessitates counseling about the risks and proper use of alprazolam along with monitoring for signs and symptoms of abuse, misuse, and addiction. Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. If a substance use disorder is suspected, evaluate the patient and institute (or refer them for) early treatment, as appropriate.
Disclosed is a nucleic acid complex which has low toxicity, is highly safe, and enables a nucleic acid molecule capable of RNA interference or the inhibition of translation (e.g., siRNA) to be retained in a cell. Also disclosed is a nucleic acid-delivering composition which can deliver the nucleic acid complex into a cell with high efficiency. A complex is produced using a nucleic acid molecule capable of RNA interference or the inhibition of translation to be introduced into a cell and cycloamylose. In this manner, a nucleic acid complex which has low toxicity, is highly safe, and enables the nucleic acid molecule to be retained in a cell can be provided. As a nucleic acid-delivering carrier for introducing the nucleic acid complex into a cell, a carrier is used which comprises (A) a diacylphosphatidylcholine, (B) cholesterol and/or a derivative thereof, and (C) an aliphatic primary amine. The carrier enables the further improvement in safety, the effectiveness of intracellular delivery, and the long-lasting ability to retain a nucleic acid molecule capable of RNA interference or the inhibition of translation in a cell.
Participants will be given the study drugs Enfortumab Vedotin and then Sacituzumab Govitecan on Days 1 and 8 of a 21-day study cycle. Dose escalation and de-escalation for the Sacituzumab Govitecan (SG) and Enfortumab vedotin-ejfv (EV) combination will be guided using the Bayesian optimal interval (BOIN) design with up to 4 dose level escalations.
The Gynocular™ examination will be performed following the steps involved in colposcopy as described in the IARC colposcopy manual. These steps include: visualization of the vagina, vulva and cervix following insertion of a speculum, magnified assessment after application of normal saline, examination of cervical vessel patterns using the red-free mode (or green filter), application of 5% acetic acid for 1 minute and finally assessment following application with Lugol's iodine. The findings of the live examination will be documented using the parameters of the Swede score. Each parameter is scored between zero and two. Treatment will be based on the results found at histopathology, unless the woman is also VIA positive in which case, after biopsy she will undergo routine treatment as per local guidelines. The results will be used to determine the optimal threshold for treatment in WLHIV.
Alcohol foam hand sanitizer applied with 1 pump into hands, spread over hands up to the wrist and rubbed until dry. Foam will be applied twice approximately 15-30 minutes apart on one day.
Information from a healthcare or dental practice application executing on a desktop computer is synchronized with information on a handheld computing device. The healthcare information from the healthcare practice application is adapted for storage in existing fields of an appropriate pre-installed application of the handheld computing device. In addition, the intended use of other fields in the appropriate application can be altered to accommodate healthcare related information. The healthcare information is preferably separated from the other information stored in the appropriate application to permit a user to quickly access the healthcare information. A separate application can be loaded onto the handheld computing device to permit a user to directly access the healthcare information. A special set of commands entered in the handheld computing device can be used when the synchronization process is started to direct the healthcare desktop application to start a process, take an action, or direct or alert a user to take action.
Assigned to 12 week waitlist, receiving usual care. Study participants assigned to the wait list will receive access to Immune Strength 12 weeks after study commencement.
All participants will consume a high-fat breakfast after an overnight fast. This meal will consist of a flour tortilla, eggs, bacon, cheddar cheese, mayonnaise, and hashbrowns. After the initial blood sample (0 min) is drawn during Visit 2, we will ask participants to consume this breakfast within 10 minutes. This meal has been designed to mimic the amount of energy (calories) and fat contained in a typical fast-food breakfast (e.g., from Tim Hortons or McDonalds). Each meal will provide 846 kcal, derived from 54 g fat (58% energy), 61 g carbohydrate (29% energy), and 29 g protein (13% energy).
Patient-Specific Bin Systems, Methods And Devices Abstract Systems, methods, and devices are described related to the assignment andmanagement of patient-specific bins. A dispensing device at a healthcare facility may include a number of bins for storage of -medical supplies, with some of -the bins designated as patient-specific bins allocated to be assigned to patients for storage of their medications or certain other supplies. A central server computer system, in communication with a computer of -the dispensing device, may monitor and assign current and future patient-specific use of the bins for the dispensing device. The assignment and -management of patient-specific bins may-be performed by devices distributed through the system. Fig. .2
The present invention relates to a suppository for thermo therapy and its application method. It is a mixed suspension preparation which is made up by making strong ferromagnetic substances, such as stainless steel, etc. into micro granule and using insertion contrast medium of iodine tincture as solvent of strong ferromagnetic micro granule. Its application method is as follows: using insertion technique to selectively inject the suppository for heat therapy into the blood-supplying vessel of tumour, applying an external alternating magnetic field and making the tumor tissue be in said alternating magnetic field. Said invention utilizes the induced vortex flow produced by strong ferromagnetic substane in alternating field to producs large heat energy to combine local high-temp. therapy and insertion suppository therapy together for curing tumour.
BACKGROUND: Attentional processing of pain has been theorized to play a key role in the severity of pain and associated disability. In particular attentional bias towards pain information, resulting in poor pain outcomes, has been extensively researched. Recently, the idea was put forward that attention bias malleability (AM), i.e., the readiness to acquire an attentional bias irrespective of its direction, may be key in predicting poor pain outcomes. We tested this hypothesis in two studies.
METHODS: In Study 1, 55 healthy participants completed an AM paradigm, followed by an experimental heat pain paradigm probing pain experience and pain-related task interference. In Study 2, 71 people with chronic pain completed an AM paradigm and questionnaires probing pain experience and associated disability.
RESULTS: In Study 1, including healthy participants, no relationship was found between AM indices and experimental pain outcomes. In Study 2, including chronic pain patients, results indicated that higher levels of overall AM were related to higher levels of pain experience and disability.
CONCLUSION: This study partially supports the hypotheses that the degree to which individuals can adapt their attentional preference in line with changing environmental conditions is associated with poor pain outcomes. However, future research is needed to clarify inconsistent findings between healthy volunteers and chronic pain patients as well as to determine the causal status of AM in poor pain outcomes.
Fibroblast growth factor receptor 1 (FGFR1) is a widely expressed, membrane-bound receptor that transduces extracellular signals from FGF ligands and cadherins, resulting in intracellular signals influencing cellular growth, proliferation, calcium, and transcription. FGF21 and FGF2 stimulate the proliferation of tanycytes, specialized radial astrocytes along the ventricle of the hypothalamus, and influence metabolism. Tanycytes are in a privileged position between the cerebrospinal fluid, the blood supply in the median eminence, and neurons within nuclei in the hypothalamus. The effect of FGFR1 signaling upon tanycyte morphology and metabolism was examined in adult mice with conditional deletion of the Fgfr1 gene using the Fgfr1flox/flox; Nestin-Cre+ line. Loss of Fgfr1 resulted in shorter β tanycytes along the medial eminence. Control Fgfr1flox/flox littermates and Fgfr1flox/flox, Nestin-Cre+ (Fgfr1 cKO) knockout mice were placed on a 1-month long high-fat diet (HFD) or a normal-fat diet (NFD), to investigate differences in body homeostasis and tanycyte morphology under an obesity inducing diet. We found that FGFR1 is a vital contributor to tanycyte morphology and quantity and that it promotes stem cell maintenance in the hypothalamus and hippocampal dentate gyrus. The Fgfr1 cKO mice developed impaired tolerance to a glucose challenge test on a HFD without gaining more weight than control mice. The combination of HFD and loss of Fgfr1 gene resulted in altered β and α tanycyte morphology, and reduced stem cell numbers along the third ventricle of the hypothalamus and hippocampus.
Participants will receive IM injection of cIPV (3 doses) at 6, 10 and 14 weeks of age. Participants will also be given a single booster vaccine of cIPV at approximately 24 weeks after the third vaccination (38 weeks of age).
PROBLEM TO BE SOLVED: To obtain an aerosol composition, having stability and excellent deodorant effects and capable of producing a natural and dry touch without causing a sense of incompatibility when used by compounding a specified powder component with a powder component, a specified surfactant and a propellant in a specific ratio. SOLUTION: This aerosol composition is obtained by compounding Nε- Iauroyl-L-lysine with a nonionic surfactant and a propellant. The amount of the compound Nε-lauroyl-L-lysine is 0.01-20.00 wt.% in the total amount of the composition. The inorganic powder is preferably a water-soluble metal salt such as chlorohydroxyaluminum or aluminum chloride and is preferably compounded in an amount of O.01-20.00 wt.%. The nonionic surfactant is preferably a glycerol fatty acid ester, a propylene glycol fatty acid ester, etc., and is preferably compounded in an amount of 0.01-10.00 wt.%. A spheroidal silicone resin having 0.5-15 μm mean particle diameter and 0.1-0.6 apparent specific gravity is preferably further compounded with the system.
###  Teratogenic Effects-Pregnancy Category C

Animal reproduction studies have not been conducted with methocarbamol. It is also not known whether methocarbamol can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. ROBAXIN Injectable should be given to a pregnant woman only if clearly needed.

Safe use of ROBAXIN Injectable has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, ROBAXIN Injectable should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see WARNINGS).
All patients will undergo the injection of a hydrogel rectal spacer (SpaceOAR) 1 week before simulation. Patients will undergo ultra-hypofractionated radiation utilizing MR-guided, daily online adaptive planning. Patients will receive 9 Gy/fraction for five fractions for a total dose of 45 Gy to the prostate DIL while the rest of the prostate will be treated to a minimum dose to the rest of the prostate of 30 Gy in five fractions. Radiation will be given every other day, Monday through Friday, until 5 treatments have been completed. Patients will be followed at three and six months after treatment, and every six months thereafter through month 24 (+/- 4 weeks).
Recently, Ombashi et al. published a systematic review aiming to identify the pitfalls in the development and implementation as well as factors influencing long-term success of a multidisciplinary, international registry for cleft care on a global scale. The purpose of this letter to the editor is to highlight that the review failed to include the Swedish quality registry for patients born with cleft lip and palate, which fulfils the inclusion criteria. The Swedish cleft lip and palate registry is multidisciplinary, has a high coverage and reporting degree, and most outcome measures have been checked for reliability and validity. It is regularly used for open comparisons between treatment centers. Several research studies have been published based on the Swedish cleft lip and palate registry, and more are ongoing. The information we provide about the Swedish cleft lip and palate registry complements and expands the information of the results reported by Ombashi et al. in their research.
<P>PROBLEM TO BE SOLVED: To provide a technique for sufficiently enhancing the melamine production-inhibiting effect of an ascorbic acid compound.  <P>SOLUTION: The subject skin care preparation for external use is characterized by containing (1) ascorbic acid and/or its derivative and (2) centaureidine having a chemical structure of the formula and/or its salt in an amount of 0.001 to 1 mass %. The ascorbic acid and/or its derivative are preferably an ascorbic acid phosphate, ascorbic acid-2-glucoside or its salt. The centaureidine is preferably prepared by subjecting an alcohol extract of a plant in the family Compositae to a solution extraction using ethyl acetate and water, concentrating the ethyl acetate phase, and then subjecting the concentrated phase to a fractional purification with column chromatography using silica gel as a carrier. The plant in the Compositae includes Achilea millefolium, Centaurea cyanus, Tanacetum parthenium, Acroptilon repens, Smallanthus sonchifolius, Lepidium meyenii, and Eupatorium rebaudianum.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Children with Developmental Language Disorder (DLD) often experience co-occurring psychosocial difficulties, the developmental trajectories of which are still not fully understood. This study sought to explore the manifestation of such difficulties during childhood, through first-hand accounts of those with DLD and their close relatives. Individual semi-structured interviews were conducted with 11 mothers of children with DLD (aged 6-12 years old) and were analysed alongside the secondary data from interviews of five adults with DLD. Interviews were conducted online; all participants resided in Europe and were fluent in spoken and written English. A process of interpretive phenomenological analysis resulted in the development of five overall themes: experiencing anxiety, social frustrations, maintaining factors, childhood strengths and the parenting experience. Cognitive appraisals appeared particularly important during childhood in both escalating and maintaining anxiety, low self-esteem, emotion dysregulation and social frustrations. High levels of isolation and stress were experienced by all mothers. The findings suggest parents in the United Kingdom and Ireland require more support and guidance at the point of diagnosis than is currently provided. Emphasis was given to the link between children's experience of anxiety and social behaviours, such as withdrawal, as well as their intolerance of uncertainty. Internalising symptoms were a prioritisation for intervention during childhood by both parents and adults with DLD.
Ultrasound (US)-guided injections will be performed with a 5-12 MHz linear transducer (Logic e portable; GE Healthcare, China) by the same physiatrist and injections will be administered into the subacromial bursa with a posterolateral approach. 3 sessions (1 session/week) of 5 mL of ozone (O2-O3) will be injected (with a concentration of 10 μg/mL in the first session, 15 μg/mL in the second session, and 20 μg/mL in the third session).
The diagnosis of MCR syndrome will be made following the criteria of Verghese et al. 5: a combination of subjective cognitive complaint, in particular of memory complaint, with the presence of an objective slow gait and the absence of dementia or mobility disability. MCR syndrome will be defined at baseline assessment and each year of follow-up period. Slow gait speed will be defined as gait speed that is one standard deviation (SD) or more below age-and sex-appropriate mean values established in the present cohort like in previous studies. The mean value and SD of female and male will be determined separately. Gait speed was determined from the 3-meter walking test using the best time of the two trials recorded and expressed as meters per second.
During this phase participants receive open label vortioxetine for 6 weeks. Participants come to the Depression Clinical \& Research Program at the Massachusetts General Hospital for visits once a week. During these visits the participants meet with clinicians and complete cognitive tasks.
The present invention relates to a traditional Chinese medicine red sage root two-phase capsule for oral administration for treating coronary heart disease and a preparation method thereof. The red sage root two-phase capsule for treating coronary heart disease extracts water-soluble and alcohol-soluble components from red sage root and notoginseng, the components are refined, concentrated and dried, granulation is carried out with a one step boiling method, and even granules are obtained; the obtained dalbergia wood volatile oil is added with supplementary materials, and drop pills or soft capsules are prepared. Finished products are obtained by placing granules and drop pills or soft capsules in hard capsules. The medicine has the advantages that the volatilization of volatile oil is reduced with the method that one liquid component and solid components are packed separately, chemical changes and physical changes caused by mixing the components are reduced, and the application of other supplementary materials is reduced. Thereby, cost is reduced, and administration quantity is reduced. Compared with red sage root tablets for treating coronary heart disease and red sage root granules for treating coronary heart disease, the red sage root two-phase capsule for treating coronary heart disease has better therapeutic effect.
INTRODUCTION: Patients with high-risk or metastatic Ewing sarcoma (ES) and rhabdomyosarcoma (RMS) have a guarded prognosis. High-dose chemotherapy (HDT) with autologous stem cell transplant (ASCT) has been evaluated as a treatment option to improve outcomes. However, survival benefits remain unclear, and treatment is associated with severe toxicities.
METHODS: A systematic review was conducted, using the population, intervention, comparison outcome (PICO) model, to evaluate whether utilization of HDT/ASCT impacts the outcome of patients with ES and RMS compared to standard chemotherapy alone, as part of first line treatment or in the relapse setting. Medline, Embase and Cochrane Central were queried for publications from 1990 to October 2022 that evaluated event-free survival (EFS), overall survival (OS), and toxicities. Each study was screened by two independent reviewers for suitability. A qualitative synthesis of the results was performed.
RESULTS: Of 1,172 unique studies screened, 41 studies were eligible for inclusion with 29 studies considering ES, 10 studies considering RMS and 2 studies considering both. In ES patients with high-risk localised disease who received HDT/ASCT after VIDE chemotherapy, consolidation with melphalan-based HDT/ASCT as first line therapy conveyed an EFS and OS benefit over standard chemotherapy consolidation. Efficacy of HDT/ASCT using a VDC/IE backbone, which is now standard care, has not been established. Survival benefits are not confirmed for ES patients with metastatic disease at initial diagnosis. For relapsed/refractory ES, four retrospective studies report improvement in outcomes with HDT/ASCT with the greatest evidence in patients who demonstrate a treatment response before HDT, and in patients under the age of 14. In RMS, there is no proven survival benefit of HDT/ASCT in primary localised, metastatic or relapsed disease.
CONCLUSION: Prospective randomised trials are required to determine the utility of HDT/ASCT in ES and RMS. Selected patients with relapsed ES could be considered for HDT/ASCT.
Participants randomized to the HCQ arm will receive HCQ 400mg po BID x 1 day, then 200mg po BID x 4 days. The drug dose (2.4 gm over 5 days) falls at the lower end of doses proposed in various international trials, but it has proven in vitro efficacy, with a ratio of lung tissue trough concentrations to the EC50 (effective concentration to suppress 50% of viral activity) of \>20.